"Drug Industry" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
| Descriptor ID |
D004345
|
| MeSH Number(s) |
J01.576.655.750
|
| Concept/Terms |
Drug Industry- Drug Industry
- Industry, Pharmaceutic
- Industries, Pharmaceutic
- Pharmaceutic Industries
- Pharmaceutic Industry
- Industry, Drug
- Drug Industries
- Industries, Drug
- Industry, Pharmaceutical
- Industries, Pharmaceutical
- Pharmaceutical Industries
- Pharmaceutical Industry
|
Below are MeSH descriptors whose meaning is more general than "Drug Industry".
Below are MeSH descriptors whose meaning is more specific than "Drug Industry".
This graph shows the total number of publications written about "Drug Industry" by people in this website by year, and whether "Drug Industry" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 2 | 5 | 7 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 3 | 5 |
| 2005 | 1 | 2 | 3 |
| 2006 | 0 | 2 | 2 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 5 | 5 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 5 | 6 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 2 | 4 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 3 | 4 |
| 2018 | 2 | 3 | 5 |
| 2019 | 0 | 3 | 3 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Industry" by people in Profiles.
-
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. Eur J Cancer. 2021 11; 157:198-213.
-
The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation. Gynecol Oncol. 2021 07; 162(1):203-209.
-
Probiotics and the Microbiome-How Can We Help Patients Make Sense of Probiotics? Gastroenterology. 2021 01; 160(2):614-623.
-
Direct-to-Consumer Drug Advertisement and Prescribing Practices: Evidence Review and Practical Guidance for Clinicians. J Gen Intern Med. 2021 05; 36(5):1390-1394.
-
Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare. Cardiovasc Drugs Ther. 2020 08; 34(4):579-584.
-
Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharmacol Ther. 2020 01; 51(1):90-109.
-
Drug-induced skin toxicity: gaps in preclinical testing cascade as opportunities for complex in vitro models and assays. Lab Chip. 2020 01 21; 20(2):199-214.
-
Joint ENGOT and GOG Foundation requirements for trials with industry partners. Gynecol Oncol. 2019 08; 154(2):255-258.
-
Joint ENGOT and GOG Foundation requirements for trials with industry partners. Int J Gynecol Cancer. 2019 09; 29(7):1094-1097.
-
The opioid epidemic in the United States-Overview, origins, and potential solutions. Cancer. 2018 11 15; 124(22):4279-4286.